Drug facts
MoleculeLorazepam (Ativan)
Generics already compete: 15 makers on the market. 32 A-rated products from 15 makers substitute at the counter.
Ativan was first approved by the FDA before 1982 under NDA 017794; the application holder is Bausch Health US LLC.
Lorazepam Injection is on the current FDA drug shortage list, first posted 05/03/2018.
Holder Bausch Health US LLCApplication NDA 017794Approved before 1982
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Ativan patent listed in the Orange Book Orange Book
- Later patents, other products
- Loreev XR 01/08/2034 Orange Book
02Competition
- Generics
- 15 generic makers Orange Book
- First generic approved
- 08/09/1985 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Lorazepam profile.See what is included
03Supply and price
- FDA drug shortage
- ActiveLorazepam Injection is on the current shortage listsince 05/03/2018, limited availability FDA shortages
- NADAC
- $0.04 per unitLORAZEPAM 1 MG TABLET, mid-priced of 3 strengths, as of 10/28/2026 CMS NADAC
- Latest recall
- 07/22/2025Class II, Lorazepam, Hikma Pharmaceuticals USA Inc. FDA enforcement
04Product
- Application holder
- Bausch Health US LLC Orange Book
- Application
- NDA 017794 Orange Book
- First approved
- before 1982 Orange Book
- Dosage forms
- capsule, extended release; concentrate; injectable; tablet
- Routes
- injection, oral
- Other brand names
- Loreev XR
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.